Mahamaya Lifesciences IPO
UpcomingAlready have an account? Apply now
Mahamaya Lifesciences IPO details
Schedule of Mahamaya Lifesciences
| Issue open date | 11 Nov 2025 |
| Issue close date | 13 Nov 2025 |
| UPI mandate deadline | 13 Nov 2025 (5 PM) |
| Allotment finalization | 14 Nov 2025 |
| Refund initiation | 17 Nov 2025 |
| Share credit | 17 Nov 2025 |
| Listing date | 18 Nov 2025 |
| Mandate end date | 28 Nov 2025 |
| Lock-in end date for anchor investors (50%) | 14 Dec 2025 |
| Lock-in end date for anchor investors (remaining) | 12 Feb 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Mahamaya Lifesciences
Incorporated in 2002, Mahamaya Lifesciences is engaged in the manufacturing of pesticide formulations and bulk supplies for Indian agrochemical companies and multinational corporations. Headquartered in Delhi with a state-of-the-art manufacturing facility at Dahej, Gujarat, the company produces and markets both branded and bulk formulations domestically and internationally. Its products are sold across major Indian states and exported to markets including the Dominican Republic, Turkey, Egypt, and the UAE.
With over three decades of promoter experience, Mahamaya Lifesciences has built strong expertise in identifying, importing, and registering new pesticide molecules with the Central Insecticides Board and Registration Committee (CIBRC). The company focuses on safer, environment-friendly crop protection solutions, supported by in-house R&D, field trials, and collaborations with agricultural universities.
Financials of Mahamaya Lifesciences
Issue size
| Category | Funds Raised (₹ crores) |
| Total issue size | 70.44 |
| Fresh Issue – Proceeds go to the company | 60.75 |
| Offer for sale – Proceeds go to the existing investors | 6.16 |
Strengths
- Wide portfolio of nutraceutical and herbal products for multiple therapeutic areas.
- ISO, GMP, and WHO-certified manufacturing facility ensuring quality standards.
- Experienced promoters with deep knowledge of pharma and healthcare sectors.
- Focus on R&D-driven product development for preventive health and wellness.
- Expanding distribution network across India and select export markets.
Risks
- Dependence on third-party distributors for sales and market reach.
- Intense competition in the nutraceutical and herbal segment.
- Regulatory changes in health product approvals may impact operations.
- Limited operating history as a public company under current structure.
- Raw material cost fluctuations may affect profitability.
Allotment Status for Mahamaya Lifesciences
To check your IPO allotment status:
- Visit the Kfin Technologies IPO Application Status page.
- Select the company name from the dropdown menu.
- Select and enter one of the following: PAN, Application Number, DP/Client ID, or Account Number/IFSC.
- Click Submit to view your allotment status